A Phase 2 interventional study of Aripiprazole + IEM (Ingestible Event Marker) in Schizophrenia, Major Depressive Disorder and Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-23.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 93rd largest by enrollment of the 125 interventional ones that give a count, is one of 3 that started in 2016, is one of 4 in phase 2, and was the 100th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 79th largest by enrollment of the 111 interventional ones that give a count, is one of 4 that started in 2016, is one of 9 in phase 2, and was the 72nd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
The Digital Medicine System includes a drug-device combination of aripiprazole + an ingestible event marker (IEM), a wearable sensor (skin patch), and application software to convey the level of activity and rest, and to mark events through the act of ingestion.
Physician and self-report are the most commonly used to assess medication compliance yet studies have consistently found that healthcare providers' subjective judgments of medication compliance are often inaccurate, with a tendency for practitioners to overestimate subject adherence. The sponsor's intent is to develop a system that will benefit future subjects by providing the ability to measure their medication-taking behavior in an objective manner and being able to monitor several physiologic parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
Drug: Aripiprazole + IEM (Ingestible Event Marker)
Drug page: Aripiprazole
Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
Also known as: MIND1, Digital Medicine System
Assessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole.
The primary outcome was assessed as the establishment of a functional and operational integrated call center with coordinated feedback to the subject and investigative site to optimize the use of DMS as measured by: 1. Inbound calls (ie, calls from the subject to the integrated call center) by help type; 2. Outbound calls (ie, calls from the integrated call center to the subject) by help type. The number presented in the table is the number of subjects in trial who made (inbound) or received (outbound) calls
Time frame: From baseline upto week 9
This open-label, single-arm trial assessed the functionality of an integrated call center for digital medicine system (DMS) as used by adult subjects (18 to 65 years of age, inclusive, at the time of screening) with Schizophrenia (SCH), Bipolar 1 disorder (BP1), or Major depressive disorder (MDD) being treated with oral aripiprazole.
| Milestone | Bipolar 1 Disorder (BP1) | Major Depressive Disorder (MDD) | Schizophrenia (SCH) |
|---|---|---|---|
| Started | 22 | 12 | 15 |
| Completed | 17 | 10 | 11 |
| Not completed | 5 | 2 | 4 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Non-compliance with patch wearing | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Non-adherence of the patch to the skin | 0 | 0 | 2 |
The primary outcome was assessed as the establishment of a functional and operational integrated call center with coordinated feedback to the subject and investigative site to optimize the use of DMS as measured by: 1. Inbound calls (ie, calls from the subject to the integrated call center) by help type; 2. Outbound calls (ie, calls from the integrated call center to the subject) by help type. The number presented in the table is the number of subjects in trial who made (inbound) or received (outbound) calls
| participants | Bipolar 1 Disorder (BP1) | Major Depressive Disorder (MDD) | Schizophrenia (SCH) |
|---|---|---|---|
| Inbound, Baseline | 0 | 0 | 1 |
| Inbound, Week 1 | 8 | 8 | 9 |
| Inbound, Week 2 | 7 | 4 | 6 |
| Inbound, Week 3 | 2 | 1 | 3 |
| Inbound, Week 4 | 4 | 2 | 5 |
| Inbound, Week 5 | 4 | 2 | 4 |
| Inbound, Week 6 | 0 | 3 | 6 |
| Inbound, Week 7 | 1 | 3 | 3 |
| Inbound, Week 8 | 2 | 0 | 4 |
| Inbound, Week >8 | 0 | 0 | 1 |
| Outbound, Baseline | 0 | 0 | 0 |
| Outbound, Week 1 | 22 | 12 | 15 |
| Outbound, Week 2 | 22 | 12 | 15 |
| Outbound, Week 3 | 6 | 4 | 3 |
| Outbound, Week 4 | 6 | 3 | 4 |
| Outbound, Week 5 | 5 | 3 | 2 |
| Outbound, Week 6 | 7 | 2 | 5 |
| Outbound, Week 7 | 9 | 4 | 4 |
| Outbound, Week 8 | 7 | 5 | 5 |
| Outbound, Week >8 | 4 | 2 | 0 |
Collected over 9 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bipolar 1 Disorder (BP1) | 0/22 (0%) | 0/22 (0%) | 10/22 (45.5%) |
| Major Depressive Disorder (MDD) | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Schizophrenia (SCH) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Event | Bipolar 1 Disorder (BP1) | Major Depressive Disorder (MDD) | Schizophrenia (SCH) |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 5/22 | 6/12 | 0/15 |
| ErythemaSkin and subcutaneous tissue disorders | 2/22 | 0/12 | 0/15 |
| SinusitisInfections and infestations | 0/22 | 1/12 | 0/15 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/22 | 1/12 | 0/15 |
| Meniscus InjuryInjury, poisoning and procedural complications | 0/22 | 1/12 | 0/15 |
| SunburnInjury, poisoning and procedural complications | 0/22 | 1/12 | 0/15 |
| HeadacheNervous system disorders | 1/22 | 1/12 | 0/15 |
| SyncopeNervous system disorders | 0/22 | 1/12 | 0/15 |
| PruritisSkin and subcutaneous tissue disorders | 1/22 | 1/12 | 0/15 |
| Skin IrritationSkin and subcutaneous tissue disorders | 0/22 | 1/12 | 0/15 |
Intent-to-treat (ITT) Sample: All subjects who entered the trial and used Digital Medicine System (DMS).
| Age, Continuous(years) | Bipolar 1 Disorder (BP1) | Major Depressive Disorder (MDD) | Schizophrenia (SCH) | Total |
|---|---|---|---|---|
| Mean | 45.5 ± 15.2 | 49.3 ± 11.2 | 45.5 ± 11.1 | 46.4 ± 13.0 |
| Sex: Female, Male(Participants) | Bipolar 1 Disorder (BP1) | Major Depressive Disorder (MDD) | Schizophrenia (SCH) | Total |
|---|---|---|---|---|
| Female | 15 | 7 | 9 | 31 |
| Male | 7 | 5 | 6 | 18 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →